Strengthening diuretics’ role in hypertension
Strengthening diuretics’ role in hypertension
MANAGED CARE September 2010. ©MediMedia USA
Back in 2002, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) examined the comparative value of different blood pressure-lowering medications. More than 33,000 patients were randomly assigned to take either a diuretic (chlorthalidone) or one of two newer drugs, a calcium channel blocker (amlodipine) or an ACE inhibitor (lisinopril). They followed these patients for four to eight years.
Researchers continued to follow these patients for an additional four to five years and the differences between the medications narrowed, but the diuretic was still superior in two measures: Patients taking the ACE inhibitor had a 20 percent higher death rate from stroke, and the calcium-channel blocker group had a 12 percent higher rate of hospitalizations and deaths caused by heart failure.
“Diuretics are a sensible starting point and an important component of any combination of drugs to help control hypertension,” says Paul Whelton, MD, president and CEO of Loyola University Health System and chairman of the ALLHAT study. “Concurrently, they are also very inexpensive.”
In the graph, chlorthalidone is the diuretic, amlodipine is the calcium channel blocker, and lisinopril is the ACE inhibitor.
Confidence intervals are used to indicate the reliability of an estimate, instead of using a single value.
Source: ALLHAT Collaborative Research Group. JAMA 2002;288:2981-97
More like this
- Fixed-Dose Triple-Combination Treatments In the Management of Hypertension
- Formulary variability challenges physicians
- ARBs already widely available on formularies for controlling hypertension
- Comparison of Amlodipine/Valsartan Fixed-Dose Combination Therapy and Conventional Therapy
- Getting ACE Inhibitors Into the Right Hands
Our other journal
P&T Journal for November 2014
Features

LETTER TO THE EDITOR
Medications for Parkinson’s Disease
PERSPECTIVE
The Changing Roles of P&T Committees
Epilepsy Management: Newer Agents, Unmet Needs, and Future Treatment Strategies
PIPELINE PLUS
Modest Growth Seen in Epilepsy Market
MEETING HIGHLIGHTS
European Society of Cardiology and Transcatheter Cardiovascular Therapeutics
BOOK REVIEW
“Generic: The Unbranding of Modern Medicine,” by Jeremy A. Greene, MD, PhD
DEPARTMENTSMEDICATION ERRORS
Misadministration of IV Insulin Associated With Dose Measurement And Hyperkalemia Treatment
PRESCRIPTION: WASHINGTON
FDA’s Proposed 503B Draft Compounding Guidance Raises Concerns of All Kinds
New Drugs/Drug News
Pharmaceutical Approval Update
DRUG FORECAST
Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension